IgA Nephropathy (IgAN) has quietly remained the most common primary glomerular disease worldwide and for decades, patients had very little beyond blood pressure control and generic immunosuppression to slow their kidney decline. That's changing, fast. EXECUTIVE SUMMARY The IgAN treatment landscape has